This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of abatacept infusion and subcutaneous injection (Orencia ®) for rheumatoid arthritis and infusion for polyarticular juvenile idiopathic arthritis as described below.
The Pan Mersey Area Prescribing Committee recommends the prescribing of adalimumab injection (Humira®) for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and in patients fitting other criteria commissioned by Pan Mersey CCGs, as described.
The Pan Mersey Area Prescribing Committee recommends the prescribing of adalimumab, etanercept and infliximab, by specialists only, for the treatment of moderate rheumatoid arthritis after conventional DMARDs have failed and in accordance with NICE TA715.